Troubled Drugmakers Mallinckrodt, Endo Officially Announce $6.7B Merger
As per the Thursday release, Endo will be folded into Mallinckrodt, which will then continue as the holding entity for the combined companies. Post-merger, the company will be listed on the New York Stock Exchange and is projected to generate around $3.6 billion in revenue this year.
(Reuters) -All drug manufacturers, including Novo Nordisk and Teva Pharmaceuticals, whose medicines are part of the second ...
The U.K. government proposes raising mandatory drug rebates paid by drug companies to bolster the National Health Service.
Despite a rocky start for many drugmakers at the start of last year, 2024’s fourth quarter saw just two of the top 25 global ...
U.S. drugmakers Johnson & Johnson and Eli Lilly increased spending on security for their top executives in 2024, citing ...
(Reuters) - Mallinckrodt and Endo, drugmakers with a shared history of facing U.S. opioid litigation, have agreed to merge in a deal valued at nearly $7 billion. Under the terms of the agreement ...
Endo and Mallinckrodt, two drugmakers seeking to recover from opioid lawsuits and bankruptcies, are betting a combination will help. Investors took a dim v ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback